BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the PharmaCare website.

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an "indication"). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

Drug information	
Generic name (scientific name)	**orforglipron**
Brand name	**TBC (to be confirmed)**
Manufacturer	Eli Lilly Canada Inc.
Indication	As an adjunct to healthy diet and physical activity to improve glycemic control for the treatment of adults with type 2 diabetes, in combination with metformin, metformin and a sulfonylurea, and metformin and a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it? (See note below.)	Yes For more information about the CDA-AMC Reimbursement Review (CRR) of orforglipron, Search the CDA-AMC Reports.
Public input start date	**Wednesday, November 18, 2026**
Public input closing date	**Tuesday, December 15, 2026, at 11:59 pm**
How is the drug taken?	Orforglipron is taken orally (by the mouth).
How often is the drug taken?	Orforglipron is taken once daily.

Drug information	
General drug and/or drug study information	The Ministry of Health is reviewing orforglipron as an adjunct to healthy diet and physical activity to improve glycemic control for the treatment of adults with type 2 diabetes, in combination with metformin, metformin and a sulfonylurea, and metformin and a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Type 2 diabetes is a common metabolic disease in which the body does not use insulin properly and, over time, may not make enough insulin to keep blood glucose levels in a healthy range. This leads to higher-than-normal levels of glucose in the blood, which, if not managed, can increase the risk of serious health problems, including heart disease, stroke, kidney disease, vision loss, and nerve damage. It is typically associated with factors such as age, family history, obesity, physical inactivity, and certain metabolic conditions, and is usually treated through healthy lifestyle changes, medications, or both. Orforglipron is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It works by activating GLP-1 receptors, which increase insulin release when blood sugar is elevated, reduce the release of glucagon (a hormone that raises blood sugar), and slow stomach emptying. Together, these effects may help lower blood sugar levels in people with type 2 diabetes.
Other considerations	None

Note:
CDA-AMC (Canada's Drug Agency-L'Agence des Médicaments du Canada) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit How PharmaCare Decides Which Drugs to Cover.

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	**Dosage Form**	**PharmaCare Status (if and how the drug is already covered)**
orforglipron (TBC)	Capsule Tablet	Under Review

Table of Comparators Used to Treat the Same Indication		
Generic Name (Brand Name) of Drug Comparator	**Dosage Form**	**PharmaCare Status (if and how the drug is already covered)**
GLP-1 Receptor Agonist		
dulaglutide (Trulicity)	Pre-filled pen	Non-Benefit
liraglutide (Victoza)	Pre-filled pen	Non-Benefit
semaglutide, injectable (generics)	Pre-filled pen	Limited Coverage
semaglutide, oral (Rybelsus)	Tablet	Non-Benefit
Glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 Receptor Agonist		
tirzepatide (Mounjaro)	Pre-filled pen	Under Review

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process.

As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit BC PharmaCare and Drug reviews for more information.

This document provides information only.
It does not take the place of advice from a physician or other qualified health care provider.